If you have been reading about hGH fragment and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Fragment analog of human growth hormone |
| Sequence basis | hGH 176–191 region | Modified C-terminal fragment |
| Common synonyms | AOD-9604; AOD9604; hGH fragment | Research and trade names vary |
| Regulatory status | Not approved as a drug | Prohibited in competitive sport |
| Research code | AOD9604 | Used in scientific and patent literature |
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Dorries eventually resigns on 26 August., 78 days after her initial announcement of "immediate effect". Boris Johnson's Resignation Honours are published. Highlights include knighthoods for Jacob Rees-Mogg and Simon Clarke, and a damehood for Priti Patel. The decision to award a life peerage to former special adviser Charlotte Owen is criticised due to her young age (29) and perceived lack of experience or contributions to British society. Johnson announces he will stand down as an MP with immediate effect after receiving the Commons Select Committee of Privileges's report into the Partygate scandal, triggering a by-election. 10 June Nigel Adams becomes the third Conservative MP in quick succession to stand down from Parliament with immediate effect, triggering a by-election. Temperatures reach above 30 °C for the first time since 24 August 2022, marking the hottest day of the year so far. Three guardsmen collapse during a military parade in London, due to the heat. Manchester City beat Inter Milan in the 2023 UEFA Champions League Final 1–0, with Rodri scoring the only goal to win the UEFA Champions League for the first time in their history. They become the second English team ever to win the Continental Treble after Manchester United in the 1998-99 Manchester United F.C. season, winning the FA Cup and the Premier League alongside the UEFA Champions League. 11 June Energy Secretary Grant Shapps, speaking on Sunday with Laura Kuenssberg, declares that the country "wants to move on" from Boris Johnson and dismisses claims the ex-PM was the victim of a "witch hunt".
Determining which amino acid forms the N-terminus of a peptide chain is useful for two reasons: to aid the ordering of individual peptide fragments' sequences into a whole chain, and because the first round of Edman degradation is often contaminated by impurities and therefore does not give an accurate determination of the N-terminal amino acid. A generalised method for N-terminal amino acid analysis follows:
Since the commissioning of the first commercial nuclear power plants (USA 1956, Germany 1962), various final storage concepts for radioactive materials have been proposed in the following decades, of which only storage in deep geological formations appeared to be safe and feasible within a reasonable period of time and was pursued further. Due to the high activity of the short-lived fission products, spent fuel is initially handled only under water and stored for several years in a decay pool. The water is used for cooling and also shields much of the emitted radiation. This is followed either by reprocessing or by decades of interim storage. Waste from reprocessing must also be stored temporarily until the heat has decreased enough to allow final disposal. Casks are special containers for the storage and transport of highly radioactive materials. Their maximum permissible dose rate is 0.35 mSv/h, of which a maximum of 0.25 mSv/h is due to neutron radiation. The safety of these transport containers has been discussed every three years since 1980 at the International Symposium on the Packaging and Transportation of Radioactive Materials (PATRAM). Following various experiments, such as the Gorleben exploratory mine or the Asse mine, a working group on the selection procedure for repository sites (AkEnd) developed recommendations for a new selection procedure for repository sites between 1999 and 2002. In Germany, the Site Selection Act was passed in 2013 and the Act on the Further Development of the Site Search was passed on March 23, 2017.
Rudolf Aebersold (better known as Ruedi Aebersold; born 12 September 1954) is a Swiss biologist, regarded as a pioneer in the fields of proteomics and systems biology. He has primarily researched techniques for measuring proteins in complex samples, in many cases via mass spectrometry. Ruedi Aebersold is a professor of Systems biology at the Institute of Molecular Systems Biology (IMSB) in ETH Zurich. He was one of the founders of the Institute for Systems Biology in Seattle, Washington, United States where he previously had a research group. Aebersold is known for the development and application of targeted proteomics techniques in the field of biomedical research, in order to understand the function, interaction and localization of each protein in the cell and its changes in disease states. To this end, Ruedi Abersold has made significant contributions in the development and application of targeted proteomics methods, including selected reaction monitoring and data-independent acquisition. Ruedi Aebersold is also recognized for its contributions in the development of standard formats and open source software for the analysis and storage of mass spectrometry and proteomics data, and he is one of the inventors of the Isotope-Coded Affinity Tag (ICAT) technique for quantitative proteomics, a technique that measures the relative quantities of proteins between two sample by using tags containing stable isotopes of different masses. Aebersold is co-founder and scientific advisor of the companies ProteoMediX and Biognosys.
O.R. Tambo is focused on most of SA's manufactured exports and imports Cape Town International deals primarily with agricultural exports, such as fruit, flowers, and seafood King Shaka International supports manufacturing and automotive exports Out of all air freight flowing through South Africa's airports, O.R. Tambo handles Major players in the South African air freight sector include South African Airways Cargo, Ethiopian Cargo, Qatar Airways Cargo, Emirates SkyCargo, Lufthansa Cargo, Turkish Cargo, and Cargolux. Freight forwarders such as DHL, FedEx, UPS, and DSV also play a large role in the sector.
Sources: en.wikipedia.org
FARC dissidents are a group formerly part of the Revolutionary Armed Forces of Colombia, who have refused to lay down their arms after the FARC-government peace treaty came into effect in 2016. The dissidents number some 1,200 armed combatants, with an unknown number of civilian militia supporting them. FARC dissidents have become "an increasing headache" for the Colombian armed forces, as they have to fight them, the EPL, ELN, and Clan del Golfo at the same time. FARC dissidents are led by former mid-level commanders such as alias "Gentil Duarte," alias "Euclides Mora," alias "John 40," alias "Giovanny Chuspas," and alias "Julián Chollo." FARC dissidents have been responsible for several attacks on Colombian armed forces. These fighters are believed to be heavily involved in the production and sale of cocaine. Dissidents of FARC's 1st Front are located in the eastern plains of Colombia. John 40 and their dissident 43rd Front moved into the Amazonas state of western Venezuela. Venezuela has served as the primary location for many FARC dissidents. On July 15, 2018, the Colombian and Peruvian governments launched a joint military effort, known as Operation Armageddon, to combat FARC dissidents. Peru issued a 60-day state of emergency in the Putumayo Province, an area bordering both Colombia and Ecuador. On the first day alone, more than 50 individuals were arrested in the operation, while four cocaine labs were dismantled. The group has attempted to recruit locals in the Putumayo Province in Peru to take up their cause.
== Division of Public Health Information Dissemination == The Public Health Informatics Office (PHIO), formerly the Division of Public Health Information Dissemination is an interdisciplinary team that collaborates across the agency and with private and governmental partners to provide innovative data, analytics, and technology solutions for public health action.
=== Isomerisation === The chiral centers of a polypeptide chain can undergo racemization. Although it does not change the sequence, it does affect the chemical properties of the sequence. In particular, the L-amino acids normally found in proteins can spontaneously isomerize at the
== References == Anderson, G.B., (1999). "Epidemiological features of chronic low back pain". The Lancet (1) 354 Langevin, H.M., Bouffard, N.A., Badger, G.J., Churchill, D.L., Howe, A.K., (2006). "Subcutaneous tissue fibroblasts cytoskeletal remodeling induced by acupuncture: evidence for a mechanotransduction-based mechanism". J Cell Physiol (3) 207 Langevin, H.M., Churchill, D.L., Cipolla, M.J., (2001). "Mechanical signalling through connective tissue: A mechanism for the therapeutic effect of acupuncture". FASEB J (1) 15
== Treatment == Antibiotic therapy to prevent streptococcal infection (prophylaxis). Steroids to suppress inflammation. Provide balanced diet in terms of calories, sodium and potassium. A low-protein diet is often recommended in chronic kidney disease, but benefits may be limited in case of glomerular disorders, the response in patients with chronic glomerulonephritis correlated closely with the effect of diet on proteinuria in these patients. Monitor for sign of kidney failure, heart failure, and hypertensive encephalopathy.
Sources: en.wikipedia.org
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.
It was investigated in clinical trials for obesity, but it did not receive approval for that use in major markets. Results were generally modest or mixed, and it remains an experimental compound.
WADA lists it as a prohibited peptide hormone. Its use can be detected by laboratory methods, and athletes are subject to sanctions if it is found in samples.
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.